Release of our first CSR Report!
We’re excited to announce the publication of our first CSR Report!
Press releases
June 3, 2024
BIOPHTA 6.5 million Euros Seed Funding
Paris, June 3, 2024
BIOPHTA, a preclinical biotech company developing a game-changing technology for the treatment of eye diseases, has just closed a € 6.5 million Seed round to bring its patented technology to clinical development.
This funding round was led by leading European VCs – UI Investissement (via the Pertinence Invest 2 Fund, advised by Mérieux Equity Partners), Elaia and GO Capital – as well as one major ophthalmology player, Unither Pharmaceuticals and HTL Biotechnology, the global leader in production and development of pharma grade biopolymers.
To see our most recent news,
follow us on LinkedIn
Read more
news from us
-
Articles April 2, 2025François Fournier Featured in Korean Press
HTL Biotechnology CEO François Fournier spoke to leading Korean media DongA Ilbo, reaffirming Korea’s strategic importance and the strong, long-standing ties with Korean customers.
-
Articles March 28, 2025HTL Biotechnology at AMWC Monaco 2025
We are excited to share that HTL Biotechnology is present at the AMWC 2025 in Monaco.
-
Articles March 11, 2025HTL Biotechnology at CIBE China
On March 10 to 12, 2025, HTL Biotechnology was proud to be present at CIBE (China International Beauty Expo) in Guangzhou, reaffirming our commitment to the dermatology and beauty industries.